Clinical Trial Update: Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage [Phase 2, Phase 3]

View source ↗

Summary

This document reports on the completed Phase 2/Phase 3 trial of subcutaneous abatacept in rheumatoid arthritis, assessing inhibition of structural damage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Orrin M Troum, M.D. and Medical Associates | Conditions: Rheumatoid Arthritis | Phase 2, Phase 3 | Status: COMPLETED